Research programme: autoimmune disorders therapeutics - Inventiva Pharma/ Abbvie

Drug Profile

Research programme: autoimmune disorders therapeutics - Inventiva Pharma/ Abbvie

Alternative Names: ABBV 157

Latest Information Update: 01 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inventiva Pharma
  • Developer AbbVie; Inventiva Pharma
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis
  • Research Autoimmune disorders

Most Recent Events

  • 19 Jul 2018 Inventiva Pharma plans a phase I trial for ABBV 157
  • 13 Sep 2017 Inventiva extended its agreement with Abbvie to develop orally available RORγ inverse agonists for autoimmune diseases
  • 09 May 2017 Preclinical trials in Psoriasis in USA (PO) before May 2017 (NCT03145948)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top